It has been estimated by NHS Choices that around half of women in the UK experience sexual problems. The most common of which involves difficulty in getting aroused – and it is this issue that pharmaceutical companies have latched on to.
Reports suggest that a drug called Lybrido (and another related drug, Lybridos) could be available by 2015. Early trials have already revealed that these drugs performed better than placebos at increasing both sexual desire and sexual satisfaction.
One of the main ingredients in Lybrido is testosterone, which increases the brain’s receptiveness to sexual cues and enhances sexual responsiveness. The drug also contains a phosphodiesterase type 5 inhibitor, which increases blood flow to the genitals in the same way as Viagra.
Lybrido is the brainchild of Netherland based company ‘Emotional Brain’ and is set to start the next stage of trials in the U.S. after being approved by the FDA. The question on everybody’s lips is: do we need it?
Some people argue that we don’t need medication for a lack of desire, because it is not an illness. Doctors appear to disagree however, calling it a disorder – hypoactive sexual desire disorder to be exact. A hotly debated article published 10 years ago warned that even the broader term for this condition, female sexual dysfunction, had been created for the benefit of drug companies.
For many women a loss of desire coincides with social reasons such as interpersonal problems, stresses at work and low self-esteem – not medical reasons. Whatever causes a lack of sexual desire, there is evidence that women would like to feel more of it again, and while existing therapies are helpful – they can take time. This could mean, for some, that medication will prove to be a useful stopgap.
If you are experiencing a lack of desire or any other sexual problems, seeking help from a counsellor could help you address the cause at its root. For more information, please see our Sexual Issues page.
View and comment on the original Guardian article.